NCT00542633View on ClinicalTrials.gov

An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

472

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

August 31, 2008

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

VIAject™

Dosage as individually required

DRUG

Regular Human Insulin

Dosage as individually required

Sponsors

Lead Sponsor

Biodel
All Listed Sponsors
lead

Biodel

INDUSTRY

NCT00542633 - An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter